Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Micron Stock Surges as Analysts Raise Price Targets Amid AI-Driven Demand

Dieter Jaworski by Dieter Jaworski
December 3, 2025
in Analysis, Nasdaq, Semiconductors, Tech & Software, Trading & Momentum
0
Micron Stock
0
SHARES
16
VIEWS
Share on FacebookShare on Twitter

Shares of memory chip leader Micron Technology are experiencing a powerful rally, underscored by a staggering 186% year-to-date gain. This momentum is mirrored in a wave of increasingly bullish analyst assessments from major investment banks, with Goldman Sachs joining the chorus on December 3 by lifting its price target. The driving forces are clear: sustained price increases for memory chips, tight inventory levels, and seemingly insatiable demand fueled by artificial intelligence. All eyes are now on whether Micron can meet these elevated expectations when it reports quarterly results on December 17.

Unquenchable AI Demand Fuels Optimism

The core of the market’s enthusiasm stems from explosive demand for high-performance memory in AI applications. Micron’s High Bandwidth Memory (HBM) products are critical components for AI accelerators from Nvidia and other chipmakers. Prices for DRAM chips have already risen approximately 50% in 2025, with forecasts suggesting a potential doubling for server DRAM by the end of 2026.

Supply remains constrained across the industry. Micron’s HBM capacity is fully booked through 2026, while competitors Samsung and SK Hynix face capacity limitations in China, which hosts 30-35% of their production. Micron’s data center business has more than doubled recently, with HBM revenue growing nearly 50% quarter-over-quarter.

A Symphony of Bullish Analyst Upgrades

Goldman Sachs is far from alone in its positive outlook. Recent weeks have seen a series of significant price target increases from prominent firms:

  • Morgan Stanley: Set a target of $338. Analyst Joseph Moore compares the current environment to the 2018 memory chip shortage and names Micron as his top pick.
  • UBS: Issued a $275 target, emphasizing that Micron’s HBM supply is completely sold out through late 2026.
  • Wolfe Research: Raised its target to $300, citing better-than-expected pricing trends.
  • BNP Paribas Exane: Upgraded the stock to “Outperform” with a $270 target, describing the start of a potential “memory super-cycle.”

Of 29 analysts covering the stock, 26 currently rate it a “Buy.” The average price target stands at $232.

Should investors sell immediately? Or is it worth buying Micron?

Goldman Sachs Details Its Bullish Case

Goldman Sachs raised its Micron price objective from $180 to $205, reiterating a Buy recommendation. Analyst James Schneider pointed to continuing price momentum in the DRAM market as the key catalyst. The bank forecasts current-quarter revenue of $13.2 billion, notably above the consensus estimate of $12.7 billion. It also sees upside potential in gross margin (projecting 53.1% vs. expectations of 51.6%) and earnings per share (forecasting $4.15 vs. $3.84).

For the February quarter, Goldman anticipates revenue of $13.7 billion and a margin approaching 55%. Schneider did caution, however, that investor expectations are already “significantly elevated,” placing enormous pressure on Micron to deliver strong results.

December 17 Earnings Report in the Spotlight

Micron is scheduled to release its Q1 2026 financial results on December 17. Expectations are high: Wall Street consensus points to revenue of $12.62 billion and adjusted earnings per share between $3.58 and $3.80—a dramatic increase from just $1.62 in the year-ago quarter. Company guidance had previously projected $12.5 billion in revenue and EPS of $3.75. Many market experts believe Micron will surpass these forecasts, given that pricing conditions have improved further since the guidance was provided.

Key focuses for the report will be the performance of the HBM business, the margins achieved, and, crucially, the company’s outlook for the remainder of 2026.

Billions in Investments Secure Future Growth

Alongside its operational performance, Micron is committing substantial capital to expand production capacity. In Japan, the company plans investments totaling $9.6 billion at its Hiroshima facility, supported by approximately $3.6 billion in subsidies from the Japanese government to advance DRAM production. In the United States, new fabrication plants are under construction in Idaho and New York, slated to begin production between 2027 and 2029. These investments could boost Micron’s share of DRAM production in the U.S. from low single-digit percentages to around 20%.

Ad

Micron Stock: Buy or Sell?! New Micron Analysis from February 7 delivers the answer:

The latest Micron figures speak for themselves: Urgent action needed for Micron investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Micron: Buy or sell? Read more here...

Tags: Micron
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Potbelly Stock
Analysis

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026
Next Post
Standard Lithium Stock

Standard Lithium Shares Maintain Analyst Confidence Amid Sector Volatility

Unitedhealth Stock

UnitedHealth Stock Gains Momentum from Strategic Shift and New Fund

Apple Stock

Apple's Stock Surge: A New Chapter in Smartphone Dominance

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com